ReviewVaccine2015
The dengue vaccine pipeline: Implications for the future of dengue control.
Review in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 131 citations in OpenAlex.
- Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease.PloS one · 2018Trial
- A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.The Journal of infectious diseases · 2016Trial
- High-Throughput Virtual Screening of Phytochemicals From Indian Medicinal Plants for the Identification of Potential Inhibitors Against NS2B-NS3 Protease of Dengue Virus.Biotechnology and applied biochemistry · 2026Article
- Unlocking Hope: Paving the Way for a Cutting-Edge Multi-Epitope Dengue Virus Vaccine.Molecular biotechnology · 2025Article
- Interplay between innate immune cells and inflammatory mediators in dengue infection: an evolving therapeutic paradigm.Expert reviews in molecular medicine · 2025Review
- Dengue: epidemiology, diagnosis methods, treatment options, and prevention strategies.Archives of virology · 2025Review
- Review
- Article
- Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses.Frontiers in immunology · 2023Article
- Article
- Production, Transmission, Pathogenesis, and Control of Dengue Virus: A Literature-Based Undivided Perspective.BioMed research international · 2021Review
- Dengue: A Minireview.Viruses · 2020Review
- Distribution and seasonal fluctuations of Ae. aegypti and Ae. albopictus larval and pupae in residential areas in an urban landscape.PLoS neglected tropical diseases · 2020Article
- Designing effective control of dengue with combined interventions.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Anti-viral activity of culinary and medicinal mushroom extracts against dengue virus serotype 2: an in-vitro study.BMC complementary and alternative medicine · 2019Article
- Prodrug Activation by a Viral Protease: Evaluating Combretastatin Peptide Hybrids To Selectively Target Infected Cells.ACS medicinal chemistry letters · 2019Article
- Force of Infection and True Infection Rate of Dengue in Singapore: Implications for Dengue Control and Management.American journal of epidemiology · 2019Article
- Point of care testing for infectious diseases.Clinica chimica acta; international journal of clinical chemistry · 2019Review
- Mimicking immune signatures of flavivirus infection with targeted adjuvants improves dengue subunit vaccine immunogenicity.NPJ vaccines · 2019Article
- Epidemiological and clinical characteristics of Dengue virus outbreaks in two regions of China, 2014 - 2015.PloS one · 2019Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Dengue has become the most rapidly expanding mosquito-borne infectious disease on the planet, surpassing malaria and infecting at least 390 million people per year. There is no effective treatment for dengue illness other than supportive care, especially for severe cases. Symptoms can be mild or life-threatening as in dengue hemorrhagic fever and dengue shock syndrome. Vector control has been only partially successful in decreasing dengue transmission. The potential use of safe and effective tetravalent dengue vaccines is an attractive addition to prevent disease or minimize the possibility of epidemics. There are currently no licensed dengue vaccines. This review summarizes the current status of all dengue vaccine candidates in clinical evaluation. Currently five candidate vaccines are in human clinical trials. One has completed two Phase III trials, two are in Phase II trials, and three are in Phase I testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.